For Immediate Release
Weight Gain and Glycemic Control in Adults with Type 1 Diabetes
Contact: Kathryn Ryan
914-740-2250
kryan@liebertpub.com
New Rochelle, NY, March 7, 2024—Significant weight gain in adults with type 1 diabetes who had good to adequate glycemic control was associated with modest deterioration in glucose control despite an increase in total daily insulin dose. These new findings are explained in greater detail in the study published in the peer-reviewed journal Diabetes Technology & Therapeutics (DTT). Click here to read the article now.
Satish Garg, MD, Editor-in-Chief of Diabetes Technology & Therapeutics, from the University of Colorado Denver, and coauthors, categorized the study participants – adults with type 1 diabetes—into four groups based on weight gain after 5 years. For participants with an enrollment HbA1c <8.0%, the mean HbA1c at year 5 was higher for those who gained >20lb compared to those with a stable weight of -5 to <5lb (7.4% vs. 7.2%, respectively) the mean total daily insulin disease at year 5 increased from 49+25 units to 61+29 units for those who gained >20 lb, while decreased from 45+27 units to 44+25 units for those with stable weight of -5 to <5lb.
“Worsening glucose control may indicate insulin resistance related to weight gain despite significant increased insulin dosage that was insufficient to maintain adequate glycemic control,” concluded the investigators.
About the Journal
Diabetes Technology & Therapeutics (DTT) is a monthly peer-reviewed journal that covers new technology and new products for the treatment, monitoring, diagnosis, and prevention of diabetes and its complications. Led by Editor-in-Chief Satish Garg, MD, University of Colorado Denver, Barbara Davis Center for Diabetes, the Journal covers breakthrough technologies and new therapeutic drug classes, behavioral aspects and approaches to diabetes care, and the latest advancements and applications of new and emerging technologies including continuous glucose monitoring, alternate insulin delivery methods, artificial pancreas, telemedicine and computerized case management, new insulins with ultra-rapid onset of action, and detection and prevention of hypoglycemia. Tables of contents and a free sample issue may be viewed on the Diabetes Technology & Therapeutics (DTT) website. DTT is the official journal of the International Conference on Advanced Technologies & Treatments for Diabetes (ATTD).
About the Publisher
Mary Ann Liebert, Inc. is a global media company dedicated to creating, curating, and delivering impactful peer-reviewed research and authoritative content services to advance the fields of biotechnology and the life sciences, specialized clinical medicine, and public health and policy. For complete information, please visit the Mary Ann Liebert, Inc. website.